Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping

Routine integration of genotype data into drug decision making could improve patient safety, particularly if many relevant genetic variants can be assayed simultaneously before prescribing the target drug. The frequency of opportunities for pharmacogenetic prescribing and the potential adverse events (AEs) mitigated are unknown. We examined the frequency with which 56 medications with known outcomes influenced by variant alleles were prescribed in a cohort of 52,942 medical home patients at Vanderbilt University Medical Center (VUMC). Within a 5‐year window, we estimated that 64.8% (95% confidence interval (CI): 64.4–65.2%) of individuals were exposed to at least one medication with an established pharmacogenetic association. Using previously published results for six medications with severe, well‐characterized, genetically linked AEs, we estimated that 383 events (95% CI, 212–552) could have been prevented with an effective preemptive genotyping program. Our results suggest that multiplexed, preemptive genotyping may represent an efficient alternative approach to current single‐use (“reactive”) methods and may also improve safety.

[1]  R. Altman,et al.  Detecting Drug Interactions From Adverse‐Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels , 2011, Clinical pharmacology and therapeutics.

[2]  H. Faruki,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, Personalized medicine.

[3]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[4]  J. Tait,et al.  Challenges and opportunities. , 1996, Journal of psychiatric and mental health nursing.

[5]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[6]  Abigail Cohen,et al.  Hospitalization costs associated with warfarin‐related bleeding events among older community‐dwelling adults , 2010, Pharmacoepidemiology and drug safety.

[7]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[8]  Shashi Amur,et al.  Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use , 2008, Pharmacotherapy.

[9]  Joshua C Denny,et al.  Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records , 2010, Genetics in Medicine.

[10]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[11]  D. Hospenthal,et al.  Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. , 2006, Military medicine.

[12]  C. Chute,et al.  Electronic Medical Records for Genetic Research: Results of the eMERGE Consortium , 2011, Science Translational Medicine.

[13]  F. Collins,et al.  The path to personalized medicine. , 2010, The New England journal of medicine.

[14]  M. Beckmann,et al.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.

[15]  E. Colman,et al.  Weighing the benefits of high-dose simvastatin against the risk of myopathy. , 2011, The New England journal of medicine.

[16]  J. A. Gómez-Capilla,et al.  Multi-mutational analysis of fifteen common mutations of the glucose 6-phosphate dehydrogenase gene in the Mediterrranean population. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[17]  D. Roden,et al.  Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record , 2012, Clinical pharmacology and therapeutics.

[18]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[19]  Marc S. Williams,et al.  A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing , 2010, PharmacoEconomics (Auckland).

[20]  D M Roden,et al.  Pharmacogenomics at the Tipping Point: Challenges and Opportunities , 2011, Clinical pharmacology and therapeutics.

[21]  W. Newman,et al.  Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? , 2010, Pharmacogenomics.

[22]  Jerry Avorn,et al.  Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation , 2009, Circulation. Cardiovascular quality and outcomes.

[23]  Jon Emery,et al.  CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis , 2005, Genetics in Medicine.

[24]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[25]  F. Schmidt Meta-Analysis , 2008 .

[26]  R. Weinshilboum,et al.  Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.

[27]  Richard L Berg,et al.  Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. , 2007, Basic & clinical pharmacology & toxicology.

[28]  R. Walensky,et al.  The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV , 2008, AIDS.

[29]  R. Steinbrook,et al.  Opportunities and Challenges for the NIH — An Interview with Francis Collins , 2009 .

[30]  J. Horowitz,et al.  Prasugrel vs. clopidogrel for cytochrome P450 2C19‐genotyped subgroups: integration of the TRITON‐TIMI 38 trial data , 2010, Journal of thrombosis and haemostasis : JTH.

[31]  Issam Zineh,et al.  DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. , 2010, Pharmacogenomics.

[32]  F. Ajmar,et al.  Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians. , 1967, The New England journal of medicine.

[33]  Francis Collins,et al.  Opportunities and challenges for the NIH--an interview with Francis Collins. Interview by Robert Steinbrook. , 2009, The New England journal of medicine.

[34]  A. Terzic,et al.  Patient-centric clinical pharmacology advances the path to personalized medicine. , 2011, Biomarkers in medicine.

[35]  T. Delea,et al.  Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. , 2010, Clinical breast cancer.

[36]  Son Doan,et al.  Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..